Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Small nuclear RNA activating complex polypeptide 3 (SNAPC3) is a subunit of the SNAPc transcription factor complex, essential for initiating transcription of small nuclear RNA (snRNA) genes by both RNA polymerase II and III. SNAPC3 binds sequence-specifically to the proximal sequence element (PSE), a conserved promoter motif in snRNA gene promoters, and helps recruit key transcription factors such as TBP (TATA-binding protein) and BRF2 to the TATA box of U6 snRNA genes, enabling accurate transcription initiation. It is located in the nucleus (nucleolus, nuclear body) and interacts with SNAPC1 and the retinoblastoma protein. While it is associated with genetic diseases such as retinitis pigmentosa, it is not currently considered a direct therapeutic target or a biomarker, and no drugs targeting SNAPC3 are known.
Not applicable (no known drug interactions)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Small nuclear RNA activating complex polypeptide 3 (SNAPC3).